Trastuzumab beyond progression for HER2 positive metastatic breast cancer: Progression-free survival on first-line therapy predicts overall survival impact

Daniel Rayson, Sarah Lutes, Gordon Walsh, Marlene Sellon, Bruce Colwell, Mark Dorreen, Arik Drucker, Alwin Jeyakumar, Tallal Younis

科研成果: 期刊稿件 › 文章 › 同行评审

13 引用 （Scopus）

指纹

探究 'Trastuzumab beyond progression for HER2 positive metastatic breast cancer: Progression-free survival on first-line therapy predicts overall survival impact' 的科研主题。它们共同构成独一无二的指纹。

Keyphrases

Immunology and Microbiology

Pharmacology, Toxicology and Pharmaceutical Science